# Pacira BioSciences Inc. (PCRX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.05B  
**Price:** $23.42 (+0.90%)

> Pacira BioSciences Inc. is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative non-opioid pain management therapies. Its primary focus is transforming patient care by providing opioid-sparing alternatives for acute, postsurgical, chronic, and musculoskeletal pain, including commercial products like EXPAREL (bupivacaine liposome injectable suspension) for long-acting local analgesia and iovera, which delivers precise cryoneurolysis to targeted nerves. The company advances solutions across the neural pain pathway, from pre-surgical preparation to rehabilitation, emphasizing enhanced recovery protocols that minimize opioid reliance. Pacira BioSciences Inc. also pursues pipeline innovations such as PCRX-201, a gene therapy candidate designed for local injection to boost IL-1Ra production and reduce chronic inflammation in osteoarthritis of the knee. Serving hospitals, ambulatory surgery centers, healthcare practitioners, and patients, the company prioritizes patient safety, rigorous quality controls, and ethical standards in research, manufacturing, and marketing. Headquartered in Tampa, Florida, Pacira BioSciences Inc. leads the shift toward non-opioid standards in pain management.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $726M | $577M | $19M | $7M | — |
| 2024 | $701M | $531M | -$73M | -$100M | — |
| 2023 | $675M | $490M | $88M | $42M | — |
| 2022 | $667M | $468M | $60M | $16M | — |
| 2021 | $542M | $401M | $90M | $42M | — |
| 2020 | $430M | $312M | $46M | $146M | — |
| 2019 | $419M | $312M | $10M | -$11M | — |
| 2018 | $332M | $246M | $16M | -$471,000 | — |
| 2017 | $284M | $196M | -$25M | -$43M | — |
| 2016 | $270M | $160M | -$32M | -$38M | — |
| 2015 | $249M | $177M | $9M | $2M | — |
| 2014 | $198M | $120M | -$5M | -$14M | — |
| 2013 | $86M | $31M | -$53M | -$64M | — |
| 2012 | $39M | $7M | -$49M | -$52M | — |
| 2011 | $16M | -$1M | -$39M | -$43M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.26B | $572M | $693M | $159M | $372M |
| 2024 | $1.55B | $775M | $778M | $277M | $585M |
| 2023 | $1.57B | $704M | $870M | $153M | $522M |
| 2022 | $1.68B | $906M | $775M | $104M | $689M |
| 2021 | $2.08B | $1.34B | $730M | $586M | — |
| 2020 | $1.27B | $655M | $620M | $100M | — |
| 2019 | $831M | $476M | $355M | $78M | — |
| 2018 | $689M | $368M | $321M | $133M | — |
| 2017 | $628M | $349M | $279M | $54M | — |
| 2016 | $391M | $172M | $219M | $36M | $109M |
| 2015 | $388M | $169M | $218M | $54M | $104M |
| 2014 | $326M | $155M | $171M | $38M | $103M |
| 2013 | $170M | $129M | $41M | $13M | $99M |
| 2012 | $112M | $46M | $66M | $13M | $25M |
| 2011 | $113M | $65M | $48M | $46M | $26M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $152M | $15M | $137M |
| 2024 | $189M | $11M | $179M |
| 2023 | $155M | $15M | $139M |
| 2022 | $145M | $30M | $115M |
| 2021 | $126M | $46M | $80M |
| 2020 | $77M | $38M | $39M |
| 2019 | $71M | $10M | $60M |
| 2018 | $49M | $15M | $34M |
| 2017 | $18M | $19M | -$1M |

Source: [CompaniesByCap](https://companiesbycap.com/company/PCRX)